Thus, combination therapy of CHEK1 inhibitor with DNA damaging agents such as TPT could introduce an analogous strategy for targeting non-BRCA mutated or BRCA-like HGS ovarian cancers. The gene discussed is CHEK1; the disease is ovarian carcinoma.